Ovid TherapeuticsOVID
Market Cap: 75.2M
About: Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
Employees: 40
Fund manager confidence
Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)
2,700% more call options, than puts
Call options by funds: $28K | Put options by funds: $1K
50% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 8
22% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 23
5% more funds holding
Funds holding: 76 [Q4 2023] → 80 (+4) [Q1 2024]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2023] → 1 (+0) [Q1 2024]
2.03% less ownership
Funds ownership: 62.43% [Q4 2023] → 60.4% (-2.03%) [Q1 2024]
8% less capital invested
Capital invested by funds: $142M [Q4 2023] → $130M (-$11.8M) [Q1 2024]
Research analyst outlook
11 Wall Street Analysts provided 1 year price forecasts over the past 6 months
11 analyst ratings
HC Wainwright & Co. Raghuram Selvaraju | 183%upside $3 | Buy Reiterated | 26 Jul 2024 |
HC Wainwright & Co. Raghuram Selvaraju | 183%upside $3 | Buy Reiterated | 2 Jul 2024 |
BTIG Thomas Shrader | 372%upside $5 | Buy Maintained | 18 Jun 2024 |
B. Riley Securities Kalpit Patel | 183%upside $3 | Buy Maintained | 18 Jun 2024 |
Citigroup Yigal Nochomovitz | 13%upside $1.2 | Neutral Maintained | 18 Jun 2024 |
Financial journalist opinion
Based on 15 articles about OVID published over the past 30 days